Pharmaids Pharmaceuticals Limited has announced that its Board of Directors will convene on February 12, 2026, to review and approve the company's unaudited financial results for the third quarter of fiscal year 2026.

Board Meeting Details

The pharmaceutical company has formally notified BSE Limited under Regulation 29 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015. The meeting will focus on considering and approving both standalone and consolidated unaudited financial results for specific reporting periods.

Trading Window Restrictions

In compliance with SEBI (Prohibition of Insider Trading) Regulations, 2015, and the company's Code of Conduct, Pharmaids Pharmaceuticals has implemented trading restrictions for designated persons. The trading window for dealing in the company's securities will remain closed for designated persons and their immediate relatives until 48 hours after the meeting outcome is declared to the stock exchange.

Corporate Communication

The notification was signed by Prasanna Subramanya Bhat, Company Secretary & Compliance Officer, on February 09, 2026. The company has indicated that this information will also be made available on its official website at www.pharmaids.com for stakeholder reference.

Company Information

Pharmaids Pharmaceuticals Limited operates with CIN: L52520KA1989PLC173979 and maintains its registered office at Unit #201, Brigade Rubix, 20/14, HMT Factory Road, Peenya Plantation, Bangalore 560013. The company's securities are listed on BSE with scrip code 524572 under the scrip ID PHARMAID.

Pharmaids Pharmaceuticals Limited has announced the completion of Mr. Mopperthy Sudheer's term as Independent Director, effective from January 05, 2026. The pharmaceutical company informed BSE Limited through a regulatory filing under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Director Term Completion Details

Mr. Mopperthy Sudheer (DIN: 00404917) ceased to hold office as Independent Director with effect from the close of business hours on January 05, 2026, upon completion of his directorship term. The company's filing, signed by Company Secretary & Compliance Officer Prasanna Subramanya Bhat, provided comprehensive details as required under regulatory guidelines.

Committee Membership Changes

Consequent to Mr. Sudheer's completion of his directorship term, he also ceased to be a member of key board committees. The director was serving on both the Audit Committee and Nomination & Remuneration Committee prior to his term completion.

Regulatory Compliance

The disclosure was made pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015. The company provided detailed information in compliance with SEBI Master Circular dated November 11, 2024, ensuring full transparency regarding the board composition change.

The regulatory filing included comprehensive details covering the director's name, reason for cessation, effective date, and other particulars as mandated by SEBI regulations. The company maintained proper compliance protocols by informing the stock exchange within the prescribed timeframe and providing all necessary documentation.